Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
1.270USD
-0.020-1.55%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
86.83MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.55%
5 Days
+0.79%
1 Month
-14.19%
6 Months
-54.80%
Year to Date
-54.80%
1 Year
-63.82%
Key Figures
1.270Open
1.305High
1.32MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.93%Turnover Ratio
1.290Prev. Close
1.200Low
914.28KTurnover
LossP/E Static
2.50P/B
0.00%Div Yield TTM
-66.82%ROA
4.55552wk High
1.21Volume Ratio
-45.45MNet Profit
68.37MShares
-0.6650EPS TTM
1.35Beta
-84.84%ROE
1.48052wk Low
8.14%Amplitude
100.00%Gross Margin
86.83MMarket Cap
-1.77Reward/Risk
4.44%Risk Rate
TradingKey Stock Score of Cardiff Oncology Inc
Currency: USD Updated: 2026-07-01Key Insights
Cardiff Oncology Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 167 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardiff Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Cardiff Oncology Inc Highlights
StrengthsRisks
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 593.00K.
Overvalued
The company’s latest PE is -1.94, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.09M shares, decreasing 30.58% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 11.24K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.39.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
7.500
Target Price
+490.55%
Upside Space
Cardiff Oncology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardiff Oncology Inc Info
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Ticker SymbolCRDF
CompanyCardiff Oncology Inc
CEOErlander (Mark)
Websitehttps://cardiffoncology.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Cardiff Oncology Inc (CRDF)?
The current price of Cardiff Oncology Inc (CRDF) is 1.29.
What is the symbol of Cardiff Oncology Inc?
The ticker symbol of Cardiff Oncology Inc is CRDF.
What is the 52-week high of Cardiff Oncology Inc?
The 52-week high of Cardiff Oncology Inc is 4.55.
What is the 52-week low of Cardiff Oncology Inc?
The 52-week low of Cardiff Oncology Inc is 1.48.
What is the market capitalization of Cardiff Oncology Inc?
The market capitalization of Cardiff Oncology Inc is 88.20M.
Is Cardiff Oncology Inc (CRDF) currently rated as Buy, Hold, or Sell?
According to analysts, Cardiff Oncology Inc (CRDF) has an overall rating of Buy, with a price target of 7.50.
What is the Earnings Per Share (EPS TTM) of Cardiff Oncology Inc (CRDF)?
The Earnings Per Share (EPS TTM) of Cardiff Oncology Inc (CRDF) is -0.69.